NeoGenomics, Inc. (FRA:NG9)

NeoGenomics Statistics

Total Valuation

NeoGenomics has a market cap or net worth of EUR 1.09 billion. The enterprise value is 1.30 billion.

Market Cap	1.09B
Enterprise Value	1.30B

Important Dates

The last earnings date was Tuesday, February 17, 2026.

Earnings Date	Feb 17, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	129.81M
Shares Outstanding	n/a
Shares Change (YoY)	+1.14%
Shares Change (QoQ)	+0.18%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	119.39M

Valuation Ratios

PE Ratio	n/a
Forward PE	63.53
PS Ratio	1.76
PB Ratio	1.53
P/TBV Ratio	49.80
P/FCF Ratio	n/a
P/OCF Ratio	244.64
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 198.41, with an EV/FCF ratio of -70.18.

EV / Earnings	-14.15
EV / Sales	2.11
EV / EBITDA	198.41
EV / EBIT	n/a
EV / FCF	-70.18

Financial Position

The company has a current ratio of 4.26, with a Debt / Equity ratio of 0.49.

Current Ratio	4.26
Quick Ratio	3.61
Debt / Equity	0.49
Debt / EBITDA	52.97
Debt / FCF	-18.80
Interest Coverage	-18.56

Financial Efficiency

Return on equity (ROE) is -12.42% and return on invested capital (ROIC) is -6.42%.

Return on Equity (ROE)	-12.42%
Return on Assets (ROA)	-2.90%
Return on Invested Capital (ROIC)	-6.42%
Return on Capital Employed (ROCE)	-5.48%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	247,787
Profits Per Employee	-36,802
Employee Count	2,500
Asset Turnover	0.49
Inventory Turnover	14.95

Taxes

Income Tax	-1.91M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -27.16% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-27.16%
50-Day Moving Average	10.16
200-Day Moving Average	7.79
Relative Strength Index (RSI)	29.40
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.35

Income Statement

In the last 12 months, NeoGenomics had revenue of EUR 619.47 million and -92.00 million in losses. Loss per share was -0.72.

Revenue	619.47M
Gross Profit	267.34M
Operating Income	-59.32M
Pretax Income	-93.92M
Net Income	-92.00M
EBITDA	-1.55M
EBIT	-59.32M
Loss Per Share	-0.72

Balance Sheet

The company has 135.95 million in cash and 348.73 million in debt, with a net cash position of -212.79 million.

Cash & Cash Equivalents	135.95M
Total Debt	348.73M
Net Cash	-212.79M
Net Cash Per Share	n/a
Equity (Book Value)	712.50M
Book Value Per Share	5.52
Working Capital	245.28M

Cash Flow

In the last 12 months, operating cash flow was 4.45 million and capital expenditures -23.00 million, giving a free cash flow of -18.55 million.

Operating Cash Flow	4.45M
Capital Expenditures	-23.00M
Free Cash Flow	-18.55M
FCF Per Share	n/a

Margins

Gross margin is 43.16%, with operating and profit margins of -9.58% and -14.85%.

Gross Margin	43.16%
Operating Margin	-9.58%
Pretax Margin	-15.16%
Profit Margin	-14.85%
EBITDA Margin	-0.25%
EBIT Margin	-9.58%
FCF Margin	n/a

Dividends & Yields

NeoGenomics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.14%
Shareholder Yield	-1.14%
Earnings Yield	-8.44%
FCF Yield	-1.70%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

NeoGenomics has an Altman Z-Score of 1.58 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.58
Piotroski F-Score	4